W.R. Berkley Corp’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

W.R. Berkley Corp’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-487,311	Closed	-$4.92M	–	347
2022 Q4	$4.92M	Buy	487,311 +199,032	+69%	+$1.99M	0.27%	65
2022 Q3	$2.86M	Buy	288,279 +239,155	+487%	+$2.36M	0.14%	138
2022 Q2	$486K	Hold	49,124	–	–	0.02%	465
2022 Q1	$484K	Hold	49,124	–	–	0.02%	472
2021 Q4	$483K	Hold	49,124	–	–	0.03%	460
2021 Q3	$478K	Hold	49,124	–	–	0.03%	364
2021 Q2	$475K	Hold	49,124	–	–	0.05%	276
2021 Q1	$477K	Buy	+49,124	New	+$476K	0.06%	237

W.R. Berkley Corp's BIOT Position: Q1 2023 in Review

W.R. Berkley Corp sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q1 2023, closing a stake of 487,311 shares — an estimated $4.92M sold.

W.R. Berkley Corp first reported a position in BIOT in Q1 2021 and held it in 8 quarters. The position peaked at $4.92M in Q4 2022. 0 funds tracked by Wall St. Rank hold BIOT as of Q1 2023.

W.R. Berkley Corp reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q1 2023 after selling out during the quarter.
W.R. Berkley Corp sold 487,311 Biotech Acquisition Company Class A Ordinary Shares shares in Q1 2023, an estimated $4.92M.
W.R. Berkley Corp first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q1 2021 and held it in 8 quarters.
W.R. Berkley Corp's Biotech Acquisition Company Class A Ordinary Shares position peaked at $4.92M in Q4 2022.
0 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q1 2023.

Based on W.R. Berkley Corp's 13F filing for Q1 2023, filed 15 May 2023.